OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-09-30-accounts

30.9.23 30.9.22
Unrestricted Total
fund funds
as restated
Notes
INCOME AND ENDOWMENTS FROM
Donations
and legacies		 33,023 17,303
Charitable
activities
Research into and education on oncology 23,603 27,129
Investment
income		 52,478 46,209
Other income 9,205 8,989
Total 118309 99,630
EXPENDITURE ON
Raising funds 19&451 19,389
Charitable
activities
Research into and education on oncology 96,222 49,652
Other
Total 115,673 69,041
Net gains/(losses) on investments 34,115 ~68,3093
NET INCOME/(EXPENDITURE) 36,811 (37,720)
RECONCILIATION OF FUNDS
Total funds brought
forward		 1,532,211 1,569,931
TOTAL FUNDS CARRIED FORWARD 1,569,022 1,532,211
30.9.23 30.9.22
Unrestricted Total
fund funds
as restated
Notes
FIXEDASSETS
Investments 12 1,293,509 1,227,599
CURRENT ASSETS
Debtors 13 34,023 25,895
Cash at bank 289,792 310,101
323,815 335,996
CREDITORS
Amounts
falling due within one year		 14 (489302) (31,384)
NET CURRENT ASSETS 275,513 304,612
TOTAL ASSETSLESSCURRENT LIABILITIES 1,569,022 1,532,211
NET ASSETS 1,569 922 1,532,211
FUNDS 15
Unrestricted
funds		 1,569,022 1,532,211
TOTAL FUNDS 1,569,022 1,532,211

30.9.23 30.9.22
as restated
Other investment
income
Deposit account interest		 51,186
1,292		 46,134
75
52,478 46,209
RAISING FUNDS
Investment
management		 costs
30.9.23 30.9.22
as restated
Portfolio management 19,451 19,389
SUPPORT COSTS
Governance
Other costs Totals
Research into and education on oncology 16,360 6,180 22,540
NET INCOME/(EXPENDITURE)
Net income/(expenditure) is stated after charging/(crediting):
30.9.23 30.9.22
as restated
Auditors' remuneration 4,560 4,380
Auditors' remuneration for non audit work 1,620 1,500

STAFF COSTS
30.9.23 30.9.22
as restated
Wages and salaries 32,306 21,026
32,306 21,026
Staffcosts are solely made up ofwages recharged fi'om various uusts during the year.
The average monthly number ofemployees during the year was as follows:
30.9.23 30.9.22
as restated
Research staff 2

COMPARATIVES FORTHE STATEMENT OF FINANCIAL ACTIVITIES
Unrestricted
fund
as restated
INCOME AND ENDOWMENTS FROM
Donations
and legacies		 17,303
Charitable
activities
Research into and educafion on oncology 27,129
Investment
income
Other income		 46,209
8,989
Total 99,630
EXPENDITURE ON
Raising funds 19,389
Charitable
activities
Research into and education on oncology 49,652
Total 69,041
Net gains/(losses)
on investments
NET INCOME/(EXPENDITURE) (37,720)
RECONCILIATION
OF FUNDS
Total funds brought
forward		 1,569,931
TOTAL FUNDS CARRIED FORWARD 1,532,211
10. PRIOR YEAR ADJUSTMENT

FIXEDASSETINVESTMENTS
Listed
investments
MARKET VALUE
At 1October 2022 I/27,599
Additions 323,910
Disposals (279,529)
Revaluations 21,529
At 30 September 2023 1,293,509
NET BOOKVALUE
At 30 September 2023 1,293,509
At 30September 2022 1,227,599

Listed
investments
Valuation
Cost		 in 2023 Z1,529
7 271,980
1,293,509
13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONK YEAR
30.9.23 30.9.22
as restated
Other debtors
Prepayments		 and accrued income 17,394
16,629		 16,446
9,449
34,023 25,895
14, CREDITORS: AMOUNTS FALLING DUE WITHIN ONK YEAR
30.9.23 30.9.22
as restated
Trade creditors 33,729 4,652
Accrued expenses 14,573 26,732
48,302 31,384

Gains Transfers
At Incoming Resources and between At
01.10.22 resources expended losses funds 30.09.23
General
Designated		 119,580 10,278 (16,609) 2,667 115,916
funds:
Breast
Development
Fighting Breast		 48&842
93,145		 1,632
3112		 (1,635)
(1,182)		 1,089
2,078		 49,928
97,153
Cancer
Prof P Hoskin
Dr A Makris
Dr P Ostler
DrKChiu
Dr M Harrison
DrN Shah
Dr D Miles		 38/71
582,790
97,511
27,394
184,809
19,110
70,721
102,602		 9,630
49,274
3/58
915
11,371
639
2,363
3,428		 (5,859)
(48,347)
(7,839)
(1,333)
(15,532)
(243)
(1,567)
(5,100)		 856
13,000
2,175
611
4,122
426
1,577
2,288		 42,998
596,717
95,105
27,587
184,770
19,932
73,094
103,218
Dr SMawdsley
DrRAlonzi		 14&804
25,341		 495
13,855		 (188)
(2,177)		 330
565		 15,441
37,584
Development 73,853 2,467 (938) 1,647 77,029
Cyberknife
Fund
Dr Westbury/Guppy
Dr Neel Bhuva		 14,244
6,598
9,582		 3,587
943
320		 (1,463)
(604)
(4,893)		 318
147
214		 16,686
7,084
5/23
Brachy 2&542 85 (32) 57 2,652
Dr Anup Vinayan 372 657 ~232) 905
1,532,211 118,309 ~215,6&3 34,175 1,569,022

for the Year Ended 3 0Se tember 2023
30.9.23 30.9.22
as restated
INCOME AND ENDOWMENTS
Donations
and legacies
Donations
Legacies		 28,023
5,000		 17,303
33,023 17,303
Investment
income
Other investment
income
Deposit account interest		 51,186
1,292		 46,134
75
52,478 46,209
Charitable
activities
Grants 23,603 27,129
Other income
Training
income
Other income		 2,407
6,798		 5,469
3,520
9/05 8,989
Total incoming
resources		 1187309 99,630
EXPENDITURE
Investment
management		 costs
Portfolio management 19,451 19,389
Charitable
activities
Research salaries 32,306 21,026
Research materials 984 6,402
Lecture fees 2,669 466
Conference 25,154 5,004
Computer
expenses		 7,517 172
Medical equipment 5,052
737682 33,070
Support costs
Other
Subscriptions 1,261 602
Administrative
expenses		 7313 6,564
Travelling 40 386
Student training 7,746 3,150
16,360 10,702
Governance
costs
Auditors'
remuneration		 4,560 4,380
Auditors'
remuneration		 for non audit work 1,620 1,500
6,180 5,880
Total resources expended ~115673 69,041
Net income before gains and losses 2,636 30,589
Realised recognised gains and losses
Realised gains/(losses) on fixed asset investments (35,074) 22,506
Net (expenditure)/income ~32,438) 53,095